TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Price, Quote, News and Overview

What is the stock price of TAKEDA PHARMACEUTIC-SP ADR today?

The current stock price of TAK is 14.27 USD. The price increased by 0.28% in the last trading session.

What is the ticker symbol for TAKEDA PHARMACEUTIC-SP ADR stock?

The exchange symbol of TAKEDA PHARMACEUTIC-SP ADR is TAK and it is listed on the New York Stock Exchange, Inc. exchange.

On which exchange is TAK stock listed?

TAK stock is listed on the New York Stock Exchange, Inc. exchange.

What is the price forecast or stock price prediction for TAKEDA PHARMACEUTIC-SP ADR stock?

22 analysts have analysed TAK and the average price target is 17.81 USD. This implies a price increase of 24.81% is expected in the next year compared to the current price of 14.27. Check the TAKEDA PHARMACEUTIC-SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.

What is TAKEDA PHARMACEUTIC-SP ADR worth?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a market capitalization of 44.91B USD. This makes TAK a Large Cap stock.

How many employees does TAKEDA PHARMACEUTIC-SP ADR have?

TAKEDA PHARMACEUTIC-SP ADR (TAK) currently has 49281 employees.

What are the support and resistance levels for TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a support level at 13.87 and a resistance level at 15.04. Check the full technical report for a detailed analysis of TAK support and resistance levels.

Is TAKEDA PHARMACEUTIC-SP ADR (TAK) expected to grow?

The Revenue of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to decline by -0.25% in the next year. Check the estimates tab for more information on the TAK EPS, Sales, EBIT and EBITDA future analyst estimates.

Should I buy TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:

• The Technical Analysis (TA) tab contains a technical analysis of TAK, looking at technical quality and support and resistance levels
• The Fundamental Analysis (FA) tab contains a fundamental analysis of TAK, evaluating the profitability, health, valuation and growth aspects
• TAKEDA PHARMACEUTIC-SP ADR (TAK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
• TAKEDA PHARMACEUTIC-SP ADR (TAK) Sales and EPS estimates to see what analysts future expectations are.
• TAKEDA PHARMACEUTIC-SP ADR (TAK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
• TAKEDA PHARMACEUTIC-SP ADR (TAK) Insider and Institutional Ownership to learn about the owners and their transactions.
• TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Chart to make your own analysis
• TAKEDA PHARMACEUTIC-SP ADR (TAK) Latest news and press-releases to stay up to date.

Does TAKEDA PHARMACEUTIC-SP ADR (TAK) stock pay dividends?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a dividend yield of 4.93%. The yearly dividend amount is currently 0.66. Check the full fundamental report for a detailed analysis of TAK dividend history, reliability and sustainability.

When does TAKEDA PHARMACEUTIC-SP ADR (TAK) report earnings?

TAKEDA PHARMACEUTIC-SP ADR (TAK) will report earnings on 2025-07-30, before the market open.

What is the Price/Earnings (PE) ratio of TAKEDA PHARMACEUTIC-SP ADR (TAK)?

The PE ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 26.43. This is based on the reported non-GAAP earnings per share of 0.54 and the current share price of 14.27 USD. Check the full fundamental report for a full analysis of the valuation metrics for TAK.

What is the Short Interest ratio of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?

The outstanding short interest for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 0.15% of its float. Check the ownership tab for more information on the TAK short interest.

ChartMill assigns a fundamental rating of 5 / 10 to TAK. While TAK has a great profitability rating, there are quite some concerns on its financial health.

Over the last trailing twelve months TAK reported a non-GAAP Earnings per Share(EPS) of 0.54. The EPS increased by 70.36% compared to the year before.

ChartMill assigns a Buy % Consensus number of 75% to TAK. The Buy consensus is the average rating of analysts ratings from 22 analysts.

For the next year, analysts expect an EPS growth of -5.52% and a revenue growth -0.25% for TAK